These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 1553250)
21. Exposure of hospital workers to airborne antineoplastic agents. deWerk Neal A; Wadden RA; Chiou WL Am J Hosp Pharm; 1983 Apr; 40(4):597-601. PubMed ID: 6846365 [TBL] [Abstract][Full Text] [Related]
22. Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process. Valero S; López-Briz E; Vila N; Solana A; Melero M; Poveda JL Regul Toxicol Pharmacol; 2018 Jun; 95():1-7. PubMed ID: 29510165 [TBL] [Abstract][Full Text] [Related]
23. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetics studies. Ensslin AS; Huber R; Pethran A; Römmelt H; Schierl R; Kulka U; Fruhmann G Int Arch Occup Environ Health; 1997; 70(3):205-8. PubMed ID: 9298404 [TBL] [Abstract][Full Text] [Related]
24. Cytotoxic drug contamination on the outside of vials delivered to a hospital pharmacy. Mason HJ; Morton J; Garfitt SJ; Iqbal S; Jones K Ann Occup Hyg; 2003 Nov; 47(8):681-5. PubMed ID: 14602675 [TBL] [Abstract][Full Text] [Related]
25. Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 122 centers. Delafoy C; Roussy C; Hudon AF; Cirtiu CM; Caron N; Bussières JF; Tanguay C J Oncol Pharm Pract; 2023 Mar; 29(2):338-347. PubMed ID: 35018847 [TBL] [Abstract][Full Text] [Related]
26. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Poupeau C; Tanguay C; Caron NJ; Bussières JF J Oncol Pharm Pract; 2018 Jan; 24(1):9-17. PubMed ID: 27799608 [TBL] [Abstract][Full Text] [Related]
27. Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. Schmaus G; Schierl R; Funck S Am J Health Syst Pharm; 2002 May; 59(10):956-61. PubMed ID: 12040735 [No Abstract] [Full Text] [Related]
28. Surface contamination with ten antineoplastic drugs in 83 Canadian centers. Chauchat L; Tanguay C; Caron NJ; Gagné S; Labrèche F; Bussières JF J Oncol Pharm Pract; 2019 Jul; 25(5):1089-1098. PubMed ID: 29726786 [TBL] [Abstract][Full Text] [Related]
29. Antineoplastic agent workplace contamination study: the Alberta Cancer Board Pharmacy perspective Phase III. Bigelow S; Schulz H; Dobish R; Chambers CR J Oncol Pharm Pract; 2009 Sep; 15(3):157-60. PubMed ID: 19171554 [TBL] [Abstract][Full Text] [Related]
30. Multicenter study of environmental contamination with antineoplastic drugs in 33 Canadian hospitals. Merger D; Tanguay C; Langlois E; Lefebvre M; Bussières JF Int Arch Occup Environ Health; 2014 Apr; 87(3):307-13. PubMed ID: 23471647 [TBL] [Abstract][Full Text] [Related]
31. Application of an Environmental Monitoring to Assess the Practices and Control the Risk of Occupational Exposure to Cyclophosphamide in Two Sites of a French Comprehensive Cancer Center. Acramel A; Fouque J; Blondeel-Gomes S; Huguet S; Rezai K; Madar O; Escalup L Ann Work Expo Health; 2022 Nov; 66(9):1215-1223. PubMed ID: 35596678 [TBL] [Abstract][Full Text] [Related]
32. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Minoia C; Turci R; Sottani C; Schiavi A; Perbellini L; Angeleri S; Draicchio F; Apostoli P Rapid Commun Mass Spectrom; 1998; 12(20):1485-93. PubMed ID: 9796535 [TBL] [Abstract][Full Text] [Related]
33. Environmental contamination with methotrexate in Canadian community pharmacies. Merger D; Tanguay C; Langlois É; Lefebvre M; Bussières JF J Am Pharm Assoc (2003); 2013; 53(4):423-6. PubMed ID: 23892817 [TBL] [Abstract][Full Text] [Related]
34. Sampling for airborne fluorouracil in a hospital drug preparation area. McDiarmid MA; Egan T; Furio M; Bonacci M; Watts SR Am J Hosp Pharm; 1986 Aug; 43(8):1942-5. PubMed ID: 3752134 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of early DNA damage in healthcare workers handling antineoplastic drugs. Ursini CL; Cavallo D; Colombi A; Giglio M; Marinaccio A; Iavicoli S Int Arch Occup Environ Health; 2006 Nov; 80(2):134-40. PubMed ID: 16761155 [TBL] [Abstract][Full Text] [Related]
36. [Antiblastic drug exposure: statistical analysis of the data coming from environmental monitoring of a site devoted to drug production]. Miraglia N; Castiglia L; Muselli A; Astarita S; Acampora A; Sannolo N G Ital Med Lav Ergon; 2007; 29(3 Suppl):739-40. PubMed ID: 18409934 [TBL] [Abstract][Full Text] [Related]
37. Study protocol for the assessment of nurses internal contamination by antineoplastic drugs in hospital centres: a cross-sectional multicentre descriptive study. Villa A; Molimard M; Bignon E; Martinez B; Rouyer M; Mathoulin-Pelissier S; Baldi I; Verdun-Esquer C; Canal-Raffin M BMJ Open; 2019 Nov; 9(11):e033040. PubMed ID: 31712349 [TBL] [Abstract][Full Text] [Related]
38. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Yoshida J; Tei G; Mochizuki C; Masu Y; Koda S; Kumagai S Ann Occup Hyg; 2009 Mar; 53(2):153-60. PubMed ID: 19261696 [TBL] [Abstract][Full Text] [Related]
39. Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents. Clark BA; Sessink PJ J Oncol Pharm Pract; 2013 Jun; 19(2):99-104. PubMed ID: 23292973 [TBL] [Abstract][Full Text] [Related]
40. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Connor TH; Anderson RW; Sessink PJ; Broadfield L; Power LA Am J Health Syst Pharm; 1999 Jul; 56(14):1427-32. PubMed ID: 10428450 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]